Syneos Health and Ride Health Partner to Improve Clinical Trial Recruitment and Retention
Syneos Health has announced a partnership with Ride Health to offer non-emergency medical transportation (NEMT) to clinical trial participants. The collaboration, built on product integration between Ride Health and the Syneos Health patient engagement platform, will enable a comprehensive transportation program for Syneos Health trials in the U.S., with a goal of expanding access. Additionally, Syneos Health made a minority investment in Ride Health as part of the strategic relationship.
Ride Health’s national transportation network integrates ride-hailing services, taxi aggregators, and higher-touch NEMT operators to provide transportation across a trial’s multi-state site footprint. The platform matches each patient’s needs to the appropriate transportation mode across standard curbside pickup, door-to-door assistance, and wheelchair accessible vehicles. Ride Health’s solution then directly connects each stakeholder through its automated communication and support systems, allowing Syneos Health to reduce the coordination burden for site staff.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
